Skip to content
Homepage
Author:
Allogene Therapeutics, Inc.
Posted Date:
May 28, 2026
Allogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics, Inc.
May 28, 2026
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics, Inc.
May 26, 2026
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Allogene Therapeutics, Inc.
May 13, 2026
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Allogene Therapeutics, Inc.
May 6, 2026
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics, Inc.
April 21, 2026
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
Allogene Therapeutics, Inc.
April 20, 2026
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
Allogene Therapeutics, Inc.
April 16, 2026
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
Allogene Therapeutics, Inc.
April 15, 2026
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
Allogene Therapeutics, Inc.
April 14, 2026
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
Allogene Therapeutics, Inc.
April 13, 2026
1
2
Next
